Clear Labs Valuation, Funding & Investors

Clear Labs is valued at $413M as of January 2025.

See full Clear Labs profile

Last Clear Labs valuation

$413M

Series D · Jan 2025

Last Clear Labs funding round

$30M

Series D · Jan 2025

Cumulative funding Clear Labs raised

$157M

across 7 funding rounds

Key investors in Clear Labs

Khosla Ventures
Felicis
Menlo Ventures
Wing Venture Capital
GV
Alumni Ventures

Jump to Section

Clear Labs Overview

About Clear Labs

Clear Labs is a Woburn-based genomics company delivering next-generation sequencing through Clear Dx for pathogen detection in infectious diseases and Clear Safety for food safety contaminants like Salmonella and E. coli. Its platforms support FDA-compliant surveillance and supply chain testing for food producers and public health agencies.

Founded

2014

HQ

San Francisco, CA

Website

clearlabs.com

Status

Privately held

Customer focus

B2B

Revenue model

Services

Valuation

$413M (Jan 2025)

Sectors

Diagnostics & Genomics Life Sciences Tools Laboratory Services BioTech DeepTech FoodTech

Clear Labs Valuation

Clear Labs is currently valued at $413M, based on its Series D in January 2025.

The $30M round was led by Alumni Ventures, with participation from Plug and Play, Menlo Ventures, Redmile Group, GV, Felicis and 6 other investors.

Clear Labs valuation by funding round

Clear Labs valuation by funding round
Date	Stage	Valuation
Jan 2025	Series D	$413M

Clear Labs Funding History

Clear Labs has raised a total of $157M across 7 funding rounds.

Clear Labs' first fundraising round was a $2M seed round in April 2014. The most recent completed round was a $30M Series D in January 2025.

Clear Labs funding rounds

Clear Labs funding rounds
Date	Stage	Investors	Raised	Valuation	Deal Summary
Jan 2025	Series D	Alumni Ventures (lead); Plug and Play; Menlo Ventures; Redmile Group; GV; Felicis; Counterpoint Global; T. Rowe Price; Khosla Ventures; HBM Genomics; Nimble Ventures; Wing Venture Capital	$30M	$413M	Clear Labs, based in San Carlos, California, develops fully automated next-generation sequencing (NGS) platforms for turnkey diagnostics, integrating DNA sequencing, robotics, and cloud-based bioinformatics to enable healthcare institutions to perform advanced genomics in-house. The company focuses on democratizing NGS for infectious diseases and aims to expand into additional markets. On January 13, 2025, Clear Labs announced a $30 million Series D funding round, led by a strategic investor with participation from existing investors including Counterpoint Global (Morgan Stanley), Felicis, GV, HBM Genomics, Khosla Ventures, Menlo Ventures, Nimble Ventures, Redmile Group, Wing Venture Capital, and funds advised by T. Rowe Price Associates. The proceeds will accelerate development and adoption of NGS solutions, scale operations to meet global demand, and support expansion to new customers and markets. Clear Labs has raised a total of $173.3 million across funding rounds from over 31 investors, including venture capital firms, private equity, strategic partners, and others like B37 Ventures, Codon Capital, Dafgårds, and Dentsu Ventures. The company's current valuation stands at $413 million, reflecting investor confidence in its growth potential, market position, and business model, potentially leading to IPO or acquisition. Alongside the financing, Clear Labs appointed Kevin Keegan, formerly Becton Dickinson’s Vice President and Global Platform Leader of Molecular Diagnostics and Illumina’s Vice President and General Manager of Oncology, to its Board of Directors to leverage his expertise for evolving needs. CEO Dr. Sasan Amini highlighted the validation from industry leaders and the technology's promise to simplify sequencing workflows and improve healthcare outcomes.
May 2021	Series C	Counterpoint Global (lead); T. Rowe Price (lead); Pfeffer Capital; Menlo Ventures; Redmile Group; GV; Felicis; Dafgårds; Khosla Ventures; Wing Venture Capital	$60M	-	Clear Labs is a biotechnology company founded in 2014 based in San Carlos, California, that develops next-generation sequencing (NGS) platforms for turnkey diagnostics. The company's flagship product, Clear Dx, is a fully automated NGS platform offering complete characterization of select pathogens, with capabilities including DNA sequencing, robotics, and cloud-based bioinformatics and analytics. The company also operates Clear Safety, a food testing platform for listeria and salmonella sequencing that uses automated NGS to replace traditional PCR, culturing, and antigen-based tests. In May 2021, Clear Labs raised $60 million in Series C funding co-led by new investors Counterpoint Global (Morgan Stanley) and T. Rowe Price Associates, with significant participation from existing investors including Redmile Group, Menlo Ventures, Wing Ventures, GV, HBM Genomics, Khosla Ventures, Felicis Ventures, and Dafgard. The round focused on accelerating innovation in pathogen screening and surveillance, particularly following the COVID-19 pandemic. The company's solutions serve both clinical and applied markets, helping organizations understand, track, and mitigate novel pathogens while improving lab efficiency and reducing costs through its automated platform approach.
May 2020	Undisclosed stage	Redmile Group (lead); Tyson Ventures; Menlo Ventures; GV; Felicis; Khosla Ventures; Wing Venture Capital	$21M	-	Clear Labs develops fully automated next-generation sequencing (NGS) platforms for turnkey diagnostics, focusing on streamlining genomic workflows for infectious diseases and healthcare applications. On May 14, 2020, the company raised $18M in a Series B - IV round led by Redmile Group, with participation from Google Ventures (GV), Khosla Ventures, and Menlo Ventures, contributing to its total funding of $135.55M across 12 rounds as of the latest data. The company continued raising capital in subsequent rounds, including a $60M Series C on May 26, 2021 with expanded investors like Morgan Stanley, T. Rowe Price, Felicis, HBM Genomics, and Wing Venture Capital, followed by a $30M Series D in January 2025 led by a strategic investor with many of the same participants. Clear Labs has demonstrated growth traction through innovative assays and enhancements to its Clear Dx platform, enabling expansion into international markets like Europe and Latin America while scaling operations for global demand in automated NGS solutions. The platform automates sequencing workflows to deliver faster, more accurate genomic insights, positioning the company as a pioneer in democratizing NGS for diagnostics. Recent developments include board additions like Kevin Keegan from Becton Dickinson to support further innovation and market adoption.
Oct 2018	Series B	Menlo Ventures (lead); Karl Handelsman; Dentsu Ventures; Felicis; B37 Ventures; Rona Holdings; Khosla Ventures; Alumni Ventures; Beast Ventures; Miguel Valls; Passport Capital; Wing Venture Capital	$21M	-	Clear Labs, based in Menlo Park, California, develops a food safety testing platform called Clear Safety that uses targeted next-generation sequencing (NGS) for pathogen detection, such as high-volume salmonella testing, with plans to expand to listeria, E. coli, campylobacter, and others. The company announced a $21 million Series B2 funding round on approximately October 30, 2018, led by Menlo Ventures, with participation from Wing Venture Capital, Dentsu Ventures, Felicis Ventures, Khosla Ventures, and unnamed food producers, bringing total funding to $45 million. Prior rounds included a $6.5 million Series A in September 2015 and $13 million Series B in December 2016. The new capital was allocated to expand features, ramp up commercial operations, and increase commercialization of the Clear Safety platform. At the time, Clear Labs had strong market traction, having signed up 90% of the U.S. poultry market, 85% of the pet food market, and 50% of third-party service labs during an initial pilot, while significantly lowering testing costs and achieving 99.9% accuracy. The company was conducting customer evaluations ahead of general availability and noted interest from federal agencies in its NGS technology for broad and deep pathogen screening. Clear Labs continued raising capital post-2018, including an $18 million Series B-IV in May 2020 led by Redmile Group, a $60 million Series C in May 2021, and a $30 million Series D in January 2025, reaching over $135 million total funding, while pivoting some efforts to COVID-19 diagnostics using its NGS platform.
Dec 2016	Series B	Wing Venture Capital (lead); Menlo Ventures; GV; Castor Ventures; Felicis; Tencent; Khosla Ventures; Alumni Ventures	$16M	-	Clear Labs is a food analytics startup founded in 2014 that develops software analyzing the molecular makeup of food to help retailers and manufacturers ensure product quality, mitigate contamination risks, verify GMO-free claims, and complement food-safety programs. The company raised $13 million in a Series B round on December 13, 2016, led by Wing Venture Capital with participation from GV (Google Ventures), Tencent, Khosla Ventures, and Felicis Ventures. This followed a $6.5 million Series A in September 2015 co-led by Khosla Ventures and Felicis Ventures, bringing total funding to $19.5 million at that point. The proceeds supported further software development, addition of more tests to the platform including next-generation sequencing-based microbiome testing and whole genome sequencing for pathogens, expansion of commercial operations in the U.S., Europe, and Asia, hiring, and licensing technology to third-party labs. Michael Taylor, former FDA deputy commissioner for foods and veterinary medicine who led the Food Safety Modernization Act, joined the board to aid government relations and industry standing. Clear Labs positioned its molecular diagnostics and data science platform to make food safety testing scalable and sustainable amid complex supply chains.
Sep 2015	Series A	Felicis (lead); Khosla Ventures (lead); Plug and Play; SGH CAPITAL; Nimble Ventures	$7M	-	Clear Labs raised $6.5 million in a Series A funding round on September 15, 2015, led by Felicis and Khosla Ventures, with participation from Nimble Ventures, Plug and Play, and SGH CAPITAL. The company develops a fully automated next-generation sequencing platform for food safety, GMO detection, allergen identification, and pathogen screening in packaged foods. Clear Labs aims to create a comprehensive molecular data index to make food indexable and searchable, shifting the paradigm from food safety to food quality for enterprise clients like food brands.
Apr 2014	Seed	Signatures Capital (lead)	$2M	-	-

Who has invested in Clear Labs?

26 investors have backed Clear Labs across its funding rounds, including Khosla Ventures, Felicis, Menlo Ventures, Wing Venture Capital, GV and Alumni Ventures.

Lead investors include Alumni Ventures, Counterpoint Global, T. Rowe Price, Redmile Group, Menlo Ventures and 4 other investors.

Clear Labs Investors

Investors in Clear Labs by funding rounds participated
Investor	HQ	Rounds	Role	First check
Felicis	San Francisco, CA	6	Lead	Sep 2015
Khosla Ventures	San Francisco, CA	6	Lead	Sep 2015
Menlo Ventures	San Francisco, CA	5	Lead	Dec 2016
Wing Venture Capital	San Francisco, CA	5	Lead	Dec 2016
GV	San Francisco, CA	4	Participant	Dec 2016
Redmile Group	San Francisco, CA	3	Lead	May 2020
Alumni Ventures	United States	3	Lead	Dec 2016
Plug and Play	San Francisco, CA	2	Participant	Sep 2015
Counterpoint Global	New York City, NY	2	Lead	May 2021
T. Rowe Price	Baltimore, MD	2	Lead	May 2021
Nimble Ventures	San Francisco, CA	2	Participant	Sep 2015
Tyson Ventures	Springdale, AR	1	Participant	May 2020
Pfeffer Capital	London	1	Participant	May 2021
SGH CAPITAL	Luxembourg	1	Participant	Sep 2015
Karl Handelsman	San Francisco, CA	1	Participant	Oct 2018
This data is available for Pro users. Sign up to see all 26 Clear Labs investors. Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Clear Labs Competitors

Clear Labs competitors include listed companies like Pacific Biosciences and Myriad Genetics, and private ones like Genesis Healthcare, Character Biosciences, Vanqua Bio and Cellanome.

Public and private companies comparable to Clear Labs
Company	HQ	Status	Revenue	EBITDA	Valuation	Revenue Multiple
Pacific Biosciences	United States	Publicly listed	$160M	($153M)	$429M	5.6x
Myriad Genetics	United States	Publicly listed	$825M	($332M)	$396M	0.6x
Genesis Healthcare	Japan	Private	-	-	$389M	-
Character Biosciences	Jersey City, NJ	Private	-	-	$356M	-
Vanqua Bio	Chicago, IL	Private	-	-	$333M	-
Cellanome	San Francisco, CA	Private	-	-	$525M	-

Clear Labs Public Comps

Clear Labs is still privately-owned, but its public comps include Prenetics Global, Indisa, Alpha Teknova, Pacific Biosciences, Myriad Genetics, Australian Clinical Labs, 908 Devices, Jiangsu Bioperfectus, Eikon Therapeutics and Tauns Laboratories.

	Last FY		EV/Revenue			EV/EBITDA
	Revenue	EBITDA	Last FY	LTM	2027E	Last FY	LTM	2027E
Prenetics Global	$92M	($33M)	3.2x	1.6x		(9.0x)	(8.3x)
Indisa	$285M	$42M	1.8x	-		12.5x	-
Alpha Teknova	$41M	($10M)	10.1x	9.2x		(40.4x)	(62.7x)
Pacific Biosciences	$160M	($153M)	5.6x	5.6x		(5.9x)	(6.9x)
Myriad Genetics	$825M	($332M)	0.6x	0.6x		(1.5x)	(16.8x)
Australian Clinical Labs	$524M	$144M	1.2x	1.1x		4.2x	4.2x
908 Devices	$56M	($33M)	6.4x	5.5x		(10.8x)	(48.4x)
Jiangsu Bioperfectus	$51M	$4M	5.7x	-		74.3x	-
Eikon Therapeutics	-	($315M)	-	-		(0.6x)	(0.5x)
Tauns Laboratories	$120M	$58M	3.9x	5.0x		8.1x	12.9x
This data is available for Pro users. Sign up to see all Clear Labs competitors and their valuation data. Start Free Trial

Common questions about Clear Labs

When was Clear Labs founded?	Clear Labs was founded in 2014.
Where is Clear Labs headquartered?	Clear Labs is headquartered in San Francisco, CA, United States.
Is Clear Labs publicly listed?	No, Clear Labs is a private, VC-backed company.
What is Clear Labs' valuation?	Clear Labs was last valued at $413M in its Series D in January 2025.
How much funding has Clear Labs raised?	Clear Labs has raised $157M across 7 funding rounds.
What was Clear Labs' last funding round?	Clear Labs' last funding round was a $30M Series D in January 2025, led by Alumni Ventures.
Who are Clear Labs' investors?	Clear Labs' investors include Felicis, Khosla Ventures, Menlo Ventures, Wing Venture Capital, GV, Redmile Group, Alumni Ventures, Plug and Play, Counterpoint Global, T. Rowe Price and 16 others.
Which companies are comparable to Clear Labs?	Companies comparable to Clear Labs include Pacific Biosciences, Myriad Genetics, Genesis Healthcare, Character Biosciences, Vanqua Bio and Cellanome.

See companies similar to Clear Labs

Pacific Biosciences

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

Myriad Genetics

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Character Biosciences

Character Biosciences is a San Francisco-headquartered therapeutics developer applying genomics, longitudinal imaging, and machine learning to uncover disease progression drivers. Collaborations with health systems build phenotyped cohorts for research into ophthalmology and neurodegeneration, yielding targeted drug candidates.

Vanqua Bio

Vanqua Bio is a Cambridge, Massachusetts-headquartered biotech firm developing therapies for neurodegenerative diseases like Parkinson's and ALS using a platform that screens human genetics and patient-derived neurons targeting lysosomal storage disorders and innate immune activation pathways.

Cellanome

Cellanome is a Redwood City-headquartered synthetic biology platform provider. The company integrates microfluidics, sensors, and multi-omics sequencing for single-cell analysis and pathway engineering. Cellanome's system accelerates CRISPR screening by processing 10,000 variants per run. Founded in 2020, it serves early-stage biotechs in the Bay Area.

Inscripta

Inscripta is a Boulder, Colorado-based gene-editing technology company, founded in 2015, that builds tools for genome engineering used in food, fuel, and healthcare applications. Its flagship product, the Onyx platform, is a benchtop system for digital microbial genome engineering that automates identifying genomic pathways, compiling them into libraries, editing them at scale with CRISPR-based tools such as the MAD7 nuclease, and analyzing the resulting effects, all within a single integrated workflow. Early commercial customers have included the University of Liverpool's GeneMill, which uses the platform to provide synthetic biology services to life-sciences and pharmaceutical partners.

GeneMind Biosciences

GeneMind Biosciences produces third-generation single-molecule gene sequencing systems, delivering advanced tools for clinicians and researchers through ongoing technological breakthroughs.

Fulgent Genetics

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Karius

Karius is a Redwood City, California-headquartered life sciences company that develops liquid biopsy tests for infectious diseases using next-generation sequencing. The Karius Test analyzes microbial cell-free DNA from blood plasma to identify bacteria, fungi, viruses, and parasites within 24 hours, aiding clinicians at hospitals like Cleveland Clinic and UCSF. Operating a CLIA-certified and CAP-accredited laboratory since 2014, Karius focuses on immunocompromised patients and sepsis cases to enable precise antibiotic stewardship.

Novogene

Novogene Co Ltd is engaged in providing multi-level scientific research and technical services and solutions for life science basic research, medical and clinical application research, and independent development and innovation of genetic testing medical equipment.

Korro Bio

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.

Immunai

Immunai is a biotechnology company with locations in New York City, San Francisco, and Tel Aviv, mapping the immune system using single-cell genomics and machine learning. The firm profiles hundreds of immune cell types from blood samples via its proprietary database, aiding biomarker discovery for therapeutics in autoimmune diseases and cancer.

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial